ProSomnus Inc News - OSA

Professional-Grade Tools, for Individual Investors.

Premium

ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results

PLEASANTON, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company” or “ProSomnus”...

ProSomnus to Design Head-to-Head Clinical Trial vs. Hypoglossal Nerve Stimulation

PLEASANTON, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP...

ProSomnus Announces Second Quarter 2023 Investor Call and Business Update

PLEASANTON, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP...

71% of Self-identified Snorers Have Never Consulted a Healthcare Professional

PLEASANTON, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP...

Data Presented at the 2023 SLEEP Annual Meeting Strengthens Evidence for ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea

PLEASANTON, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP...

Data Presented at the 2023 American Academy of Dental Sleep Medicine and the American Thoracic Society Meetings Further Validate ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea

PLEASANTON, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a leading...

ProSomnus Reports First Quarter 2023 Financial Results

PLEASANTON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company” or “ProSomnus”...

ProSomnus Announces Q1 2023 Investor Call and Participation in Upcoming Investor Conferences

PLEASANTON, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a...

Study to be Presented at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference Demonstrates Efficacy of ProSomnus Precision Oral Appliances

PLEASANTON, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a...

ProSomnus® Announces Publication of Four Accepted Abstracts in the Journal of Dental Sleep Medicine in Advance of Annual Meeting

PLEASANTON, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a...

ProSomnus® Receives Additional U.S. Utility Patent Covering Iterative Titration Technology for Company’s Novel Precision Sleep Apnea Medical Devices

PLEASANTON, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a...

ProSomnus Reports Fourth Quarter and Fiscal Year 2022 Financial Results

PLEASANTON, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a...

ProSomnus® Receives Patent Allowance Covering Automated Manufacturing Process for Company’s Novel Precision Sleep Apnea Medical Devices

PLEASANTON, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a...

ProSomnus to Host Investor Call and Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023

PLEASANTON, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), the...

ProSomnus® Announces Acceptance of Abstract at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference

PLEASANTON, Calif., March 10, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a...

Renee 5 months ago

OSAPQ: BK PLAN effective. All shares and warrants cancelled.

https://otce.finra.org/otce/dailyList?viewType=Deletions

👍️0

Renee 8 months ago

Effective May 9,2024 OSAP will change to OSAPQ, bankruptcy.

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

👍️0

Renee 9 months ago

OSA changed to OSAP. Delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

👍️0

TrendTrade2016 1 year ago

OSA here comes 1.20

👍️0

TrendTrade2016 1 year ago

OSA wants 1.20

👍️0

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

ProSomnus Inc (OSA)

Professional-Grade Tools, for Individual Investors.

OSA News

ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results

ProSomnus to Design Head-to-Head Clinical Trial vs. Hypoglossal Nerve Stimulation

ProSomnus Announces Second Quarter 2023 Investor Call and Business Update

71% of Self-identified Snorers Have Never Consulted a Healthcare Professional

Data Presented at the 2023 SLEEP Annual Meeting Strengthens Evidence for ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea

Data Presented at the 2023 American Academy of Dental Sleep Medicine and the American Thoracic Society Meetings Further Validate ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea

ProSomnus Reports First Quarter 2023 Financial Results

ProSomnus Announces Q1 2023 Investor Call and Participation in Upcoming Investor Conferences

Study to be Presented at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference Demonstrates Efficacy of ProSomnus Precision Oral Appliances

ProSomnus® Announces Publication of Four Accepted Abstracts in the Journal of Dental Sleep Medicine in Advance of Annual Meeting

ProSomnus® Receives Additional U.S. Utility Patent Covering Iterative Titration Technology for Company’s Novel Precision Sleep Apnea Medical Devices

ProSomnus Reports Fourth Quarter and Fiscal Year 2022 Financial Results

ProSomnus® Receives Patent Allowance Covering Automated Manufacturing Process for Company’s Novel Precision Sleep Apnea Medical Devices

ProSomnus to Host Investor Call and Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023

ProSomnus® Announces Acceptance of Abstract at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference

OSA Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

ProSomnus Inc (OSA) News

ProSomnus Inc (OSA)

Professional-Grade Tools, for Individual Investors.

OSA News

ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results

ProSomnus to Design Head-to-Head Clinical Trial vs. Hypoglossal Nerve Stimulation

ProSomnus Announces Second Quarter 2023 Investor Call and Business Update

71% of Self-identified Snorers Have Never Consulted a Healthcare Professional

Data Presented at the 2023 SLEEP Annual Meeting Strengthens Evidence for ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea

Data Presented at the 2023 American Academy of Dental Sleep Medicine and the American Thoracic Society Meetings Further Validate ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea

ProSomnus Reports First Quarter 2023 Financial Results

ProSomnus Announces Q1 2023 Investor Call and Participation in Upcoming Investor Conferences

Study to be Presented at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference Demonstrates Efficacy of ProSomnus Precision Oral Appliances

ProSomnus® Announces Publication of Four Accepted Abstracts in the Journal of Dental Sleep Medicine in Advance of Annual Meeting

ProSomnus® Receives Additional U.S. Utility Patent Covering Iterative Titration Technology for Company’s Novel Precision Sleep Apnea Medical Devices

ProSomnus Reports Fourth Quarter and Fiscal Year 2022 Financial Results

ProSomnus® Receives Patent Allowance Covering Automated Manufacturing Process for Company’s Novel Precision Sleep Apnea Medical Devices

ProSomnus to Host Investor Call and Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023

ProSomnus® Announces Acceptance of Abstract at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference

OSA Discussion

Your Recent History

Go Ad-Free